Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDV/SOF Retreatment in Genotype 1 HCV
NCT01987453Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 5
01
Overview
Phase 2, open-label trial of Harvoni in hepatitis C (HCV) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event up to 24 weeks. Started Jul 2014; status: completed.
02
Drugs
Harvoni
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01987453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01987453.